. Author manuscript; available in PMC: 2020 Jun 2.

Published in final edited form as: J Neurosurg Pediatr. 2018 Dec 7;23(3):333–342. doi: 10.3171/2018.9.PEDS17225

TABLE 1.

Cumulative adverse events: severity and causality

Maximum Severity	Any Relationship (n = 54)	Attribution to Study Procedure (n = 21)	Attribution to Study Drug (n = 16)	Unrelated to Study (n = 17)	Resolved (n = 39)	Unresolved (n = 15)
Grade 1	29 (54%)	13	8	8	27	2
Grade 2	23 (43%)	8	8	7	11	12
Grade 3	2 (3%)	0	0	2	1	1
Grade 4	0	0	0	0	0	0
Grade 5^*	0	0	0	0	0	0

All patients ultimately died from progression of the underlying disease (documented MRI progression of disease process beyond its extent at the time of infusion).